Unzueta A, Valdez R, Chang Yu-Hui H, Desmarteau YM; Heilman RL, Scott RL, Douglas DD, Rakela J

Language: English
References: 21
Page: 33-40
PDF size: 152.96 Kb.

ABSTRACT

Background. Acute hepatitis E virus (HEV) infection in solid organ transplant recipients is rare, but can cause severe hepatic and extrahepatic complications. We sought to identify the pretransplant prevalence of HEV infection in heart and kidney candidates and any associated risk factors for infection. Material and methods. Stored frozen serum from patients undergoing evaluation for transplant was tested for HEV immunoglobulin G (IgG) antibodies and HEV RNA. All patients were seen at Mayo Clinic Hospital, Phoenix, Arizona, with 333 patients evaluated for heart (n = 132) or kidney (n = 201) transplant. HEV IgG antibodies (anti-HEV IgG) were measured by enzyme-linked immunosorbent assay, and HEV RNA by a noncommercial nucleic acid amplification assay. Results. The prevalence of anti-HEV IgG was 11.4% (15/132) for heart transplant candidates and 8.5% (17/201) for kidney transplant candidates, with an overall seroprevalence of 9.6% (32/333). None of the patients tested positive for HEV RNA in the serum. On multivariable analysis, age older than 60 years was associated with HEV infection (adjusted odds ratio, 3.34; 95% CI, 1.54-7.24; P = 0.002). Conclusions. We conclude that there was no evidence of acute HEV infection in this pretransplant population and that older age seems to be associated with positive anti-HEV IgG.

REFERENCES

1. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-9.

2. Moal V, Motte A, Kaba M, Gerolami R, Berland Y, Colson P. Hepatitis E virus serological testing in kidney transplant recipients with elevated liver enzymes in 2007-2011 in southeastern France. Diagn Microbiol Infect Dis 2013; 76: 116-8.

3. Legrand-Abravanel F, Kamar N, Sandres-Saune K, Garrouste C, Dubois M, Mansuy JM, Muscari F, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis 2010; 202: 835-44.

4. Unzueta A, Rakela J. Hepatitis E infection in liver transplant recipients. Liver Transpl 2014; 20(1): 15-24.

5. Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, et al. Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. N Engl J Med 2014; 370: 1111-20.

6. Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, Ganzenmueller T, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant 2012; 12: 3128-33.

7. Moal V, Legris T, Burtey S, Morange S, Purgus R, Dussol B, Garcia S, et al. Infection with hepatitis E virus in kidney transplant recipients in southeastern France. J Med Virol 2013; 85: 462-71.

8. Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis 2009; 200: 48-56.

9. Ivo D, Fausta D, Pardha D, Calistus D, Patrick SK, Michael C. Current epidemiology of hepatitis E virus infection in the United States: Low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology 2014; 60: 815-22.

10. Legrand-Abravanel F, Kamar N, Sandres-Saune K, Lhomme S, Mansuy JM, Muscari F, Sallusto F, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis 2011; 17: 30-7.

11. Nelson KE, Kmush B, Labrique AB. The epidemiology of hepatitis E virus infections in developed countries and among immunocompromised patients. Expert Rev Anti Infect Ther 2011; 9: 1133-48.

12. Wenzel JJ, Preiss J, Schemmerer M, Huber B, Jilg W. Test performance characteristics of anti-HEV IgG assays strongly influence hepatitis e seroprevalence estimates. J Infect Dis 2013; 207: 497-500.

13. Drobeniuc J, Meng J, Reuter G, Greene-Montfort T, Khudyakova N, Dimitrova Z, Kamili S, et al. Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances. Clin Infect Dis 2010; 51: e24-e27.

14. Pas SD, Streefkerk R, Pronk M, de Man RA. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol 2013; 58: 629-34.

15. Baylis SA, Blumel J, Mizusawa S, Matsubayashi K, Sakata H, Okada Y, Nubling C, et al. World health organization international standard to harmonize assays for detection of hepatitis e virus RNA. Emerg Infect Dis 2013; 19: 729-35.

16. Danziger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant 2013; 13(Suppl. 4): 311-7.

17. Wedemeyer H, Pethig K, Wagner D, Flemming P, Oppelt P, Petzold DR, Haverich A, et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998; 66: 1347.

18. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-42.

19. Carbone M, Mutimer D, Neuberger J. Hepatitis C virus and non liver solid organ transplantation. Transplantation 2013; 95: 779-86.

20. Fagiuoli S, Minniti F, Pevere S, Farinati F, Burra P, Livi U, Naccarato R, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 2001; 20: 718-24.

21. Faramawi MF, Johnson E, Chen S, Pannala PR. The incidence of hepatitis e virus infection in the general population of the USA. Epidemiol Infect 2011; 139(8): 1145-50.